News Conference News AHA 2025 CRISPR-Cas9 Gene-Editing Therapy Shows Early Promise for Dyslipidemia Todd Neale November 08, 2025
News Conference News TCT 2025 At 3 Years, DCBs Still Less Safe Than DES in De Novo CAD: REC-CAGEFREE I Yael L. Maxwell November 07, 2025
News Conference News TCT 2025 ‘Investing’ in CTOs With Staged PCI Seems to Pay Off in Safety Gains Yael L. Maxwell November 05, 2025
News Opinion Editor's Corner AHA 2025 What’s Going to Be Hot at AHA 2025? Michael O'Riordan November 05, 2025
News Conference News TCT 2025 What Makes MedTech Great—or Not—and Envisioning Its Future Caitlin E. Cox November 04, 2025
News Conference News TCT 2025 iFR-Guided Immediate PCI Not Superior to Deferred CMR-Guided Strategy in STEMI Yael L. Maxwell October 28, 2025
News Conference News TCT 2025 STRIVE: Low-Dose Alteplase Ineffective in STEMI Patients With Large Thrombus Michael O'Riordan October 28, 2025
News Conference News TCT 2025 ENCIRCLE: Good Results With Sapien M3 Transseptal TMVR Todd Neale October 27, 2025
News Conference News TCT 2025 LIFE-BTK: 3-Year Data Keep Dissolving Scaffold’s Durability Hopes Alive in CLTI L.A. McKeown October 27, 2025
News Conference News TCT 2025 Tendyne Safely Reduces MR in Patients With Severe Calcification: SUMMIT-MAC Yael L. Maxwell October 27, 2025
News Conference News TCT 2025 PREVUE-VALVE Charts the Prevalence of Valve Disease in the United States Caitlin E. Cox October 27, 2025
Presentation TCT 2025 TCT 595: Cardiac Damage Staging in Moderate or Greater Aortic Regurgitation: A New Framework for Risk Stratification Presenter: Francisco Alexandrino October 27, 2025
News Conference News TCT 2025 Sirolimus-Coated Balloon Meets Mark in De Novo Lesions and ISR: SELUTION Michael O'Riordan October 26, 2025
News Conference News TCT 2025 More Data on Tricuspid Valve Interventions Reassure, yet Questions Remain Yael L. Maxwell October 26, 2025
News Conference News TCT 2025 Trials Bolster Alternatives to Intravascular Lithotripsy for Calcified Lesions Todd Neale October 26, 2025
Presentation TCT 2025 Rationale and Status of “At Risk” Moderate AS Trials (PROGRESS and EXPAND TAVR II) Presenter: Josep Rodés-Cabau October 26, 2025
Presentation TCT 2025 TCT 149: Prediction of Percutaneous Coronary Intervention Success in Moderate-to-severe Coronary Artery Calcification Patients Using Machine Learning Based on Coronary Angiography Presenter: Zixiang Ye October 26, 2025
Presentation TCT 2025 TCT 152: Sex-related differences in the prevalence and clinical outcomes of moderate-to-severe coronary artery calcification Presenter: Zhangyu Lin October 26, 2025
Presentation TCT 2025 TCT 126: Association between optimal revascularization for moderate-to-severe coronary artery calcification and long-term outcomes in patients with heart failure with different glucose metabolism statuses Presenter: Zhangyu Lin October 26, 2025
News Conference News TCT 2025 TTVR Remains Safe, Effective in Presence of CIED Leads Todd Neale October 25, 2025